RXST

Over the past six months, RxSight's stock price has been volatile, closing at $4.81 on October 9, 2026, after a 40.7% loss over the preceding 12 months. Key events include a 14.45% drop on May 6, 2026, following first-quarter 2026 results that reiterated full-year sales outlook but reported an increased net loss. On July 6, 2026, the stock saw a modest 0.36% increase after announcing a collaboration with Alcon. The company's stock increased by 6.10% on July 15, 2026, following the appointments of Aziz Mottiwala as CEO and Ron Kurtz, M.D. as CMO. On July 26, 2026, the stock rose by 8.67% due to reports of inducement grants. The stock declined by 3.34% on August 5, 2026, and increased by 3.61% on August 26, 2026. An insider exercised options on September 16, 2026.